Gemcitabine Hydrochloride with or without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen with or without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients with Pancreatic Cancer That Has Been Removed by Surgery
Inclusion Criteria
- Histologic proof of primary head of pancreas invasive adenocarcinoma managed with a potentially curative resection (i.e., removal of all gross tumor) involving a classic pancreaticoduodenectomy (Whipple) or a pylorus preserving pancreaticoduodenectomy; patients with invasive adenocarcinoma that also contains a component of intraductal papillary mucinous neoplasm (IPMN) are eligible * The operating surgeon must document in the operative note that a complete gross excision of the primary tumor was achieved; the pathology report must include documentation of the margin status and the size of the tumor; the pathology report must also include the status of the three major margins—bile duct, pancreatic parenchyma, and retroperitoneal (uncinate)
- For patients who have not started their chemotherapy prior to registration, the interval between definitive tumor-related surgery and 1st step registration must be between 21-70 days; for patients entering on the study who have already received up to 3 months of adjuvant chemotherapy as per the treating institution, the interval between definitive tumor-related surgery and day one of adjuvant chemotherapy must be between 21-77 days
- Patients will be staged according to the 6th edition American Joint Committee on Cancer (AJCC) staging system with pathologic stage T1-3, N0-1, M-0 being eligible
- Zubrod performance status 0 or 1
- Complete history and physical examination including weight and Zubrod status within 31 days of study entry (or within 31 days prior to day 1 of chemotherapy post-surgery for those patients having started chemotherapy prior to first step registration)
- Before starting therapy the patient should be able to maintain adequate oral nutrition of >= 1500 calories estimated caloric intake per day and be free of significant nausea and vomiting
- Complete blood count (CBC)/differential obtained within 21 days of registration on study (or within 21 days prior to day 1 of chemotherapy post-surgery for those patients having started chemotherapy prior to first step registration)
- Absolute neutrophil count (ANC) >= 1,500/mm^3
- Platelets >= 100,000/mm^3
- Hemoglobin (Hgb) >= 8.0 g/dL (transfusion or other intervention to achieve Hgb >= 8.0 g/dl is acceptable)
- Post resection serum cancer antigen (CA)19-9 =< 180 units/mL AND prior to any systemic treatment
- Serum total bilirubin =< twice the institutional upper limit of normal (ULN) within 21 days of registration on study (or within 21 days prior to day 1 of chemotherapy post-surgery for those patients having started chemotherapy prior to first step registration)
- Creatinine levels =< twice the institutional upper limit of normal within 21 days of registration on study (or within 21 days prior to day 1 of chemotherapy post-surgery for those patients having started chemotherapy prior to first step registration)
- Serum glutamic oxaloacetic transaminase (SGOT) must be =< 2.5 x institutional ULN within 21 days of registration on study (or within 21 days prior to day 1 of chemotherapy post-surgery for those patients having started chemotherapy prior to first step registration)
- Negative serum pregnancy test for women of childbearing potential within 14 days of study registration
- Abdominal/pelvic computed tomography (CT) scan with contrast is preferred; abdominal CT alone is acceptable only if insurance restrictions are experienced; chest CT/x-ray (CT of chest preferred) within 31 days of registration on study (or within 31 days prior to day 1 of chemo post-surgery for those patients having started chemotherapy prior to first step registration); patients allergic to intravenous (IV) contrast can have magnetic resonance imaging (MRI) of the abdomen/pelvis instead
- Signed study-specific informed consent
- Consultation, agreement, and documentation in the patient’s chart by a radiation oncologist that patient is suitable to receive radiotherapy per this protocol
- Women of childbearing potential and male participants must practice adequate contraception
- Patients with active human immunodeficiency virus (HIV) infection are eligible if their cluster of differentiation (CD)4 count is > 499/cu mm and their viral load is < 50 copies/ml; use of highly active antiretroviral treatment (HAART) is allowed
Exclusion Criteria
- Patients with non-adenocarcinomas, adenosquamous carcinomas, islet cell (neuroendocrine) tumors, cystadenomas, cystadenocarcinomas, carcinoid tumors, duodenal carcinomas, distal bile duct, and ampullary carcinomas; patients with tumors that are largely IPMN with a minimal or minor component of invasive carcinoma are not eligible; patients with acinar carcinomas are not eligible; patients with IPMN’s that contain some secondary (minor) foci of adenocarcinoma are also not eligible
- Patients managed with a total pancreatectomy, a distal pancreatectomy, or central pancreatectomy
- Patients entering on the study after pancreaticoduodenectomy, who have not already started chemotherapy must not have had prior systemic chemotherapy for pancreas cancer; note that prior chemotherapy for a different cancer is allowable; for patients entering on the study who have already received up to 3 months of adjuvant chemotherapy as per the treating institution, patients must not have received adjuvant chemotherapy with agents other than gemcitabine, nab-paclitaxel, oxaliplatin, fluoropyrimidine, or irinotecan for the current pancreatic cancer; prior chemotherapy for a different cancer is allowable
- Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
- Previous history of invasive malignancy (except non-melanoma skin cancer) unless the patient has been disease free for at least 2 years prior to study entry (or first day of chemotherapy for patients having started chemotherapy prior to first step registration); patients with a previous history of carcinoma in situ are eligible
- Severe, active co-morbidity, defined as follows per time points indicated below (or per time points indicated below prior to the first day of chemotherapy for patients having started chemotherapy prior to first step registration): * Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months * Transmural myocardial infarction within the 3 months of study registration * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
- Pregnant or lactating women
- Women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception
- If surgical margin status cannot be determined after consultation with the operating surgeon and the institutional pathologist, the patient will be ineligible
Alabama
Mobile
Alaska
Anchorage
Arizona
Scottsdale
California
Auburn
Burbank
Burlingame
Cameron Park
Carmichael
Castro Valley
Clovis
Duarte
Dublin
Emeryville
Fremont
Fresno
Greenbrae
La Jolla
Los Angeles
Martinez
Modesto
Mountain View
Oakland
Orange
Palo Alto
Pleasanton
Rancho Cordova
Redwood City
Richmond
Rohnert Park
Roseville
Sacramento
Saint Helena
San Diego
San Francisco
San Jose
San Leandro
San Pablo
San Rafael
Santa Clara
Santa Rosa
South San Francisco
Stockton
Sunnyvale
Vacaville
Vallejo
Walnut Creek
Colorado
Aurora
Boulder
Colorado Springs
Denver
Durango
Englewood
Fort Collins
Golden
Grand Junction
Greeley
Greenwood Village
Lakewood
Littleton
Lone Tree
Longmont
Loveland
Parker
Pueblo
Thornton
Wheat Ridge
Connecticut
Bridgeport
Hartford
Meriden
New Britain
Norwich
Delaware
Lewes
Newark
Rehoboth Beach
Seaford
Wilmington
District of Columbia
Washington
Florida
Coral Gables
Deerfield Beach
Fort Lauderdale
Gainesville
Jacksonville
Jupiter
Miami
Miami Beach
Orlando
Panama City
Trinity
Georgia
Atlanta
Columbus
Gainesville
Savannah
Hawaii
Aiea
Honolulu
Idaho
Boise
Fruitland
Lewiston
Meridian
Nampa
Post Falls
Twin Falls
Illinois
Alton
Arlington Heights
Aurora
Bloomington
Canton
Carthage
Chicago
Danville
Decatur
Effingham
Elmhurst
Eureka
Galesburg
Geneva
Harvey
Kankakee
Kewanee
Macomb
Mattoon
Maywood
Mount Vernon
Naperville
Normal
Ottawa
Pekin
Peoria
Peru
Plainfield
Princeton
Rockford
Springfield
Urbana
Warrenville
Yorkville
Indiana
Beech Grove
Elkhart
Fort Wayne
Goshen
Indianapolis
Kokomo
La Porte
Michigan City
Mishawaka
Plymouth
Richmond
South Bend
Westville
Iowa
Ames
Boone
Clive
Des Moines
Jefferson
Marshalltown
Sioux City
West Des Moines
Kansas
Chanute
Dodge City
El Dorado
Fort Scott
Independence
Kingman
Lawrence
Liberal
Manhattan
McPherson
Newton
Overland Park
Parsons
Prairie Village
Pratt
Salina
Topeka
Wellington
Wichita
Winfield
Kentucky
Lexington
Louisiana
New Orleans
Shreveport
Maryland
Baltimore
Glen Burnie
Salisbury
Massachusetts
Boston
Burlington
Fall River
Pittsfield
Springfield
Michigan
Adrian
Ann Arbor
Brownstown
Clinton Township
Commerce
Detroit
Escanaba
Farmington Hills
Grand Rapids
Iron Mountain
Kalamazoo
Livonia
Monroe
Muskegon
Pontiac
Royal Oak
Saint Joseph
Troy
Warren
West Bloomfield
Wyoming
Minnesota
Burnsville
Coon Rapids
Edina
Fridley
Maplewood
Minneapolis
Robbinsdale
Rochester
Saint Louis Park
Saint Paul
Waconia
Willmar
Mississippi
Jackson
Pascagoula
Missouri
Bolivar
Bonne Terre
Branson
Cape Girardeau
Columbia
Creve Coeur
Independence
Jefferson City
Joplin
Kansas City
Lee's Summit
Liberty
Rolla
Saint Joseph
Saint Louis
Saint Peters
Sainte Genevieve
Springfield
Sullivan
Sunset Hills
Montana
Billings
Bozeman
Butte
Great Falls
Helena
Kalispell
Missoula
Nebraska
Grand Island
Kearney
Lincoln
Omaha
Nevada
Henderson
Las Vegas
Reno
New Hampshire
Manchester
New Jersey
Basking Ridge
Camden
Livingston
Middletown
Mount Holly
Newark
Paramus
Ridgewood
Sparta
Voorhees
Westwood
New York
Albany
Brooklyn
Canandiaqua
Commack
Glens Falls
Lake Success
Middletown
Mineola
New Hyde Park
New York
Rochester
Sleepy Hollow
Stony Brook
Uniondale
West Harrison
North Carolina
Charlotte
Concord
Greenville
Hendersonville
Kinston
Matthews
Raleigh
Rutherfordton
Winston-Salem
Ohio
Akron
Alliance
Barberton
Belpre
Bowling Green
Chillicothe
Cincinnati
Cleveland
Columbus
Dayton
Delaware
Elyria
Findlay
Franklin
Independence
Kettering
Lancaster
Lima
Marietta
Maumee
Mayfield Heights
Medina
Mount Vernon
Newark
Oregon
Portsmouth
Ravenna
Salem
Sandusky
Springfield
Strongsville
Sylvania
Tiffin
Toledo
Troy
Wauseon
West Chester
Westerville
Wooster
Xenia
Zanesville
Oklahoma
Oklahoma City
Tulsa
Oregon
Bend
Clackamas
Gresham
Milwaukie
Newberg
Oregon City
Portland
The Dalles
Pennsylvania
Abington
Allentown
Bryn Mawr
Danville
Darby
Drexel Hill
Dunmore
Easton
Gettysburg
Hanover
Media
Natrona Heights
Paoli
Philadelphia
Sayre
Upland
West Reading
Wilkes-Barre
Wynnewood
York
Rhode Island
Providence
South Carolina
Anderson
Boiling Springs
Charleston
Easley
Greenville
Greer
Lancaster
Rock Hill
Seneca
Spartanburg
South Dakota
Rapid City
Sioux Falls
Tennessee
Nashville
Texas
Amarillo
Arlington
Austin
Bedford
Flower Mound
Fort Worth
Galveston
Houston
League City
Lewisville
Longview
McKinney
Round Rock
San Antonio
Sherman
Sugar Land
Temple
Tyler
Webster
Utah
American Fork
Cedar City
Logan
Murray
Ogden
Provo
Saint George
Salt Lake City
Virginia
Fredericksburg
Hampton
Norfolk
Virginia Beach
Washington
Auburn
Bellevue
Centralia
Everett
Federal Way
Gig Harbor
Lacey
Lakewood
Longview
Olympia
Puyallup
Spokane
Tacoma
Vancouver
West Virginia
Charleston
Morgantown
Wheeling
Wisconsin
Antigo
Chippewa Falls
Eau Claire
Green Bay
La Crosse
Marinette
Marshfield
Milwaukee
Minocqua
New Richmond
Oconto Falls
Rhinelander
Rice Lake
Stevens Point
Sturgeon Bay
Wausau
Weston
Wisconsin Rapids
Wyoming
Casper
Sheridan
Ontario
London
Ottawa
Quebec
Montreal
Belgium
Brussels
Kortrijk
Turnhout
Israel
Petach Tikva
Tel Aviv
Tel Hashomer
PRIMARY OBJECTIVES:
I. To determine whether the addition of erlotinib (erlotinib hydrochloride) to gemcitabine (gemcitabine hydrochloride) adjuvant chemotherapy shows a signal for improved survival as compared to gemcitabine alone following R0 or R1 resection of head of pancreas adenocarcinoma (including adenocarcinoma of the head, neck, and uncinate process). (Phase II-R)
II. To determine whether the use of concurrent fluoropyrimidine and radiotherapy following adjuvant gemcitabine based chemotherapy or non-gemcitabine based chemotherapy such as modified fluorouracil-leucovorin-irinotecan-oxaliplatin regimen (FOLFIRINOX) further enhances survival for such patients who are without evidence of progressive disease after 5 months of adjuvant chemotherapy. (Phase III)
SECONDARY OBJECTIVES:
I. To evaluate disease-free survival of adjuvant chemotherapy followed by radiotherapy and concurrent fluoropyrimidine for patients with resected head of pancreas adenocarcinoma who are disease free after 5 months of adjuvant chemotherapy.
II. To evaluate disease-free survival of standard adjuvant gemcitabine chemotherapy with and without erlotinib for patients with resected head of pancreas adenocarcinoma.
III. To evaluate adverse events with and without erlotinib for patients with resected head of pancreas adenocarcinoma.
IV. To evaluate adverse events of adjuvant chemotherapy with or without radiation therapy and concurrent fluoropyrimidine for patients with resected head of pancreas adenocarcinoma who are disease free after adjuvant chemotherapy.
V. To evaluate preoperative cross-sectional imaging of the primary head of pancreas adenocarcinoma in order to determine the frequency with which objective criteria of resectability are present.
VI. To determine if patients reporting low baseline fatigue, as measured by the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue, predicts survival and to explore correlations between baseline fatigue, as measured by Patient-Reported Outcomes Measurement Information System (PROMIS), and survival.
OUTLINE: Patients without disease progression after treatment in arm I or II are randomized to 1 of 2 additional treatment arms (arm III or IV).
ARM I: Patients receive either gemcitabine hydrochloride or allowable combination chemotherapy per standard of care for 5 months.
ARM II (closed to accrual 4/2/14): Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1, 8, and 15 and erlotinib hydrochloride orally (PO) once daily on days 1-28. Treatment repeats every 28 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
ARM III: Patients receive the same treatment as in arm I for 1 month.
ARM IV: Patients receive the same treatment as in arm I for 1 month. Beginning within 7-21 days after completion of chemotherapy, patients undergo radiotherapy (3-dimensional conformal radiotherapy or intensity-modulated radiotherapy) 5 days per week for 5.5 weeks (28 fractions). During radiotherapy, patients receive either capecitabine PO twice daily (BID) 5 days per week or fluorouracil IV continuously for 5.5 weeks or until radiotherapy is completed.
After completion of study treatment, patients are followed up periodically.
Trial Phase Phase III
Trial Type Treatment
Lead Organization
NRG Oncology
Principal Investigator
Ross Allen Abrams
- Primary ID RTOG-0848
- Secondary IDs NCI-2011-01987, 11-00773, CDR0000659092, RTOG 0848
- Clinicaltrials.gov ID NCT01013649